EXPAREL® (Pacira, US)
EXPAREL® (PACIRA, US) is an injectable product for single-dose administration into the surgical site to produce post-surgical analgesia. Vectura recognised £6.6m within other revenue during 2017 (2016 proforma underlying: £5.8m) which equates to a 3% share of Pacira's cash receipts from net sales of EXPAREL®. Vectura is also eligible to receive a further sales milestone of $32m when worldwide annual net sales of the product reach $500m (on a cash-received basis); the receipt of this milestone is not patent dependent.
ADVATE® (Baxter, Global)
ADVATE® (BAXTER, GLOBAL) is an antihaemophilic factor (recombinant) for the treatment of haemophilia A and marketed worldwide by Baxter. Vectura’s ADVATE® patent expired at the end of January 2016; however, due to higher than anticipated production of ADVATE® inventory by Baxter prior to this expiry, Vectura has continued to receive royalties from sales of this product totalling £1.0m for 2017 (2016 proforma: £13.7m). Vectura does not anticipate further material royalties from sales of this product.
Solaraze® (Sandoz US and Almirall EU)
SOLARAZE® (SANDOZ US AND ALMIRALL EU) is a non-steroidal anti-inflammatory drug (NSAID) treating actinic keratosis, a precancerous skin growth usually caused by sun exposure. Solaraze® royalties were £2.9m for 2017 (2016 proforma underlying: £6.7m).
Adept® (Baxter, Global)
ADEPT® (BAXTER, GLOBAL) is a 4% icodextrin solution used during surgery to reduce post-surgical adhesions, a frequent and major complication after gynaecological and other abdominal surgery. Adept® continues to make a minor contribution to royalty revenue.
Find out more on the Skyepharma website www.skyepharma.fr